Answers are grounded in this paper and cite their sources.
Chemoselective macrocyclization of unprotected peptides in aqueous media is essential for generating large screening libraries and advancing hit compounds toward therapeutic candidates; however, developing a broadly applicable strategy remains challenged by incomplete conversion, cross-reactivity with proteogenic side chains, and linker instability. Here, we report an azetidinedriven sulfur(VI) fluoride exchange (AzetSuFEx) platform to address these bottlenecks. Leveraging the high nucleophilicity of azetidine, SuFEx cyclization proceeds quantitatively across neutral and basic aqueous conditions, delivers stable linkers, and exhibits high chemoselectivity across 20 canonical amino acids. This selectivity enables a modular, one-pot multicyclization strategy by pairing AzetSuFEx with amine-, phenolate-, and thiolate-driven chemistries to cleanly construct diverse bicyclic architectures. Furthermore, extending AzetSuFEx to intermolecular systems overcomes the proximity constraints of conventional SuFEx bioconjugation, enabling multi-site functionalization under dilute conditions. By combining quantitative aqueous efficiency, proteogenic compatibility, and proximity-free bioconjugation, AzetSuFEx provides a practical platform for the discovery of macrocyclic peptide and bioconjugate therapeutics.
No takes yet. Share an insight, caveat, or question.
Mi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: